Streetbeat News

Stock Prices

LEN

Lennar Corporation's stock (LEN) has declined by 26% over the past three months. Investors are considering whether this presents a buying opportunity.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

CLS

CLS has experienced a 240% growth, driven by its diverse portfolio of products essential for AI applications. The company is expected to continue this growth trajectory into 2025.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

HD

LOW

The article compares Lowe's (LOW) and Home Depot (HD) to determine which company is better positioned for growth by 2025. Both companies have been strong competitors in the home improvement industry for over a decade.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

ADDYY

NKE

Nike's stock is near its 52-week lows, while Adidas is close to its highs as we enter 2025. Investors are evaluating which company presents a better investment opportunity.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

AMGN

Amgen is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, which could provide insights into the company's future plans and performance.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

DYN

Dyne Therapeutics, Inc. (Nasdaq: DYN) will release new clinical data from its Phase 1/2 ACHIEVE trial on January 10, 2025, and host a webcast to discuss the findings.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

ROOT

Root, Inc. (NASDAQ: ROOT) will participate in the 27th Annual ICR Conference from January 13-15, 2025, in Orlando, Florida. This participation may provide visibility and networking opportunities for the company.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

NVDA

QBTS

Nvidia CEO Jensen Huang's comments on quantum computers being decades away led to a drop in shares of D-Wave Quantum and its peers. D-Wave CEO Alan Baratz disagrees, stating that the company has significant paying clients currently.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

CLDI

Calidi Biotherapeutics, a clinical-stage biotechnology company, announced a proposed public offering of its common stock and/or pre-funded warrants. The company plans to sell all shares itself.

Portfolio Pulse from

January 08, 2025 | 9:15 pm

ZYME

Zymeworks Inc. (Nasdaq: ZYME) has announced its strategic priorities for 2025 and 2026, focusing on developing novel biotherapeutics for diseases like cancer, inflammation, and autoimmune disorders.

Portfolio Pulse from

January 08, 2025 | 9:15 pm